XNASGHRS
Market cap364mUSD
Dec 23, Last price
7.00USD
1D
2.19%
1Q
-4.37%
IPO
-64.29%
Name
GH Research PLC
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
Net income
-36m
L+398.77%
CFO
-33m
L+27.24%
Profile
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate; and GH003, an intranasal 5-MeO-DMT product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | |||||
Cost of revenue | 41,501 | 30,601 | 15,119 | ||
Unusual Expense (Income) | |||||
NOPBT | (41,501) | (30,601) | (15,119) | ||
NOPBT Margin | |||||
Operating Taxes | (15,321) | 9 | |||
Tax Rate | |||||
NOPAT | (41,501) | (15,280) | (15,128) | ||
Net income | (35,587) 398.77% | (7,135) -22.54% | (9,211) 1,965.25% | ||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 15 | 309,200 | |||
BB yield | 0.00% | -25.48% | |||
| Debt | |||||
Debt current | 343 | ||||
Long-term debt | 1,605 | ||||
Deferred revenue | |||||
Other long-term liabilities | 1,868 | ||||
Net debt | (220,754) | (251,679) | (276,776) | ||
| Cash flow | |||||
Cash from operating activities | (33,336) | (26,199) | (15,283) | ||
CAPEX | (100) | (67) | (104) | ||
Cash from investing activities | (54,100) | (84,688) | (104) | ||
Cash from financing activities | (204) | 286,447 | |||
FCF | (42,473) | (14,978) | (15,527) | ||
| Balance | |||||
Cash | 161,560 | 165,955 | 276,776 | ||
Long term investments | 61,142 | 85,724 | |||
Excess cash | 222,702 | 251,679 | 276,776 | ||
Stockholders' equity | (72,495) | (41,632) | (14,273) | ||
Invested Capital | 292,437 | 291,448 | 291,448 | ||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 52,023 | 52,021 | 52,021 | ||
Price | 5.80 -40.33% | 9.72 -58.34% | 23.33 | ||
Market cap | 301,731 -40.33% | 505,643 -58.34% | 1,213,646 | ||
EV | 80,977 | 253,964 | 936,870 | ||
EBITDA | (41,186) | (30,554) | (15,100) | ||
EV/EBITDA | |||||
Interest | 723 | 8,098 | 9 | ||
Interest/NOPBT | |||||